FindMyKOL

Hal Chadow, MD

Basic profile

SUNY Downstate Health Sciences University

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionBrooklyn, NY · NortheastSpecialtyCardiovascular DiseaseFocusCardiology
Active KOLEmergingFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Hal Chadow is a Cardiology physician affiliated with SUNY Downstate Health Sciences University. OpenAlex indexes 50 publications with 1,171 citations (h-index 9).

Overview

Scholarship

indexed output and impact (OpenAlex)
50publications

Publications indexed by OpenAlex. Counts exclude supporting files.

1,171citations

Citations across these publications.

9h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
53companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

53 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Stryker Corporation
    Program year20256 payments
    $4,494
  • Canon Medical Systems USA, Inc.
    Program year20253 payments
    $545
  • Novartis Pharmaceuticals Corporation
    Program year202522 payments
    $354
All 114 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    72.5%
    Statin13%
    Atorvastatin Calcium93%Rosuvastatin Calcium7%
    Part D<11 patients
    Calcium channel blocker12.9%
    Nifedipine Er78%Amlodipine Besylate23%
    Part D≥61 patients

    + 12 more classes in this area

  • Metabolism & gastrointestinal

    11.9%
    SGLT2 inhibitor5.5%
    Farxiga62%Jardiance38%
    Part D≥29 patients
    Proton pump inhibitor1.7%
    Pantoprazole Sodium61%Omeprazole39%
    Part D<11 patients

    + 5 more classes in this area

  • Blood & clotting

    11.6%
    P2Y12 inhibitor7.2%
    Brilinta56%Clopidogrel44%
    Part D≥28 patients
    Factor Xa inhibitor3.5%
    Xarelto57%Eliquis43%
    Part D<11 patients

    + 1 more class in this area

Where care is delivered (Part B)78.4% facility · 21.6% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”